Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Cenobamate Formulations
NCT04690751Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cenobamate in focal onset seizure (3 arms), sponsored by SK Life Science, Inc. Primary endpoints: Maximum Observed Plasma Concentration at 456 hours, Time to Maximum Observed Plasma Concentration at 456 hours and 2 more. Started Dec 2020; status: completed.
02
Drugs
cenobamate
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT04690751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690751.